Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California Johns Hopkins, Baltimore, Maryland SCRI Oncology Partners, Nashville, Tennessee The University of Texas MD Anderson Cancer Center, Houston, Texas